uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, recently declared its fiscal results for the third quarter of 2k19 and highlighted recent progress across its business.
Cash Position: As of September 30, 2k19, the Company held cash and cash equivalents of $403.20M, contrast to $184.10M as of June 30, 2k19. The Company presently anticipates cash and cash equivalents will be sufficient to fund operations into 2k22.
Revenues: Revenue for the 3-months finished September 30, 2k19 was $1.00M, contrast to $3.10M throughout the similar duration 2k18. The decline reflects the October 2k18 termination of the development of S100A1 under our partnershipwith Bristol-Myers Squibb.
R&D Costs: Research and development costs were $23.60M for the 3-months finished September 30, 2k19, contrast to $20.50M throughout the similar duration 2k18. The change was mainly related to increased activities associated with our ongoing clinical studies of etranacogene dezaparvovec, the planned Phase I/II study of AMT-130, increased share-based compensation and the hiring of additional clinical and operations staff at our Lexington site.
SG&A Costs: Selling, general and administrative costs were $8.90M for 3-months finished September 30, 2k19, contrast to $5.90M throughout the similar duration 2k18. The change was mainly related to inclines in personnel and consulting costs, professional fees and share-based compensation costs.
Net Loss: The net loss for the 3-months finished September 30, 2k19 was $23.60M, or $0.580 for each share, contrast to $22.00M, or $0.590 for each share throughout the similar duration 2k18.